← Back to Search

Contrast Agent

BAY1747846 for Contrast Enhancement in Magnetic Resonance Imaging

Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after administration of study intervention up to day 12 (± 2 days)
Awards & highlights

Study Summary

This trial will help researchers learn more about how BAY1747846 moves in, through and out of the body, which will help them understand how safe and effective the agent is.

Eligible Conditions
  • Contrast Enhancement in Magnetic Resonance Imaging

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after administration of study intervention up to day 12 (± 2 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and after administration of study intervention up to day 12 (± 2 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the concentration versus time curve from zero to infinity of BAY1747846 after single dose administration (AUC)
Maximum observed drug concentration of BAY1747846 in plasma after single dose administration (Cmax)
Total body clearance of BAY1747846 normalized by body weight
Secondary outcome measures
Number of participants with treatment-emergent adverse events
Number of participants with treatment-emergent adverse events categorized by severity

Trial Design

3Treatment groups
Experimental Treatment
Group I: Normal renal functionExperimental Treatment1 Intervention
Participants with normal renal function will receive a single dose of BAY1747846.
Group II: Moderate renal impairmentExperimental Treatment1 Intervention
Participants with moderate renal impairment will receive a single dose of BAY1747846.
Group III: Mild renal impairmentExperimental Treatment1 Intervention
Participants with mild renal impairment will receive a single dose of BAY1747846.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BAY1747846
2021
Completed Phase 1
~50

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

BayerLead Sponsor
2,236 Previous Clinical Trials
25,325,554 Total Patients Enrolled
7 Trials studying Contrast Enhancement in Magnetic Resonance Imaging
2,586 Patients Enrolled for Contrast Enhancement in Magnetic Resonance Imaging

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Investigative RadiologyJournal
Preclinical Profile of Gadoquatrane
Lohrke, Jessica, Markus Berger, Thomas Frenzel, Christoph-Stephan Hilger, Gregor Jost, Olaf Panknin, Marcus Bauser, Wolfgang Ebert, and Hubertus Pietsch. 2022. “Preclinical Profile of Gadoquatrane”. Investigative Radiology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/rli.0000000000000889.
Investigative RadiologyJournal
Preclinical Profile of Gadoquatrane
Lohrke, Jessica, Markus Berger, Thomas Frenzel, Christoph-Stephan Hilger, Gregor Jost, Olaf Panknin, Marcus Bauser, Wolfgang Ebert, and Hubertus Pietsch. 2022. “Preclinical Profile of Gadoquatrane”. Investigative Radiology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/rli.0000000000000889.
clinicaltrials.govStudy
A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function
2021. "A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05061979.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top